Other adverse predictors included male sex, AML‐MRC, R/R disease, TP53, ASXL1, RUNX1, and SRSF2, monosomy 17 or 17p abnormalities, complex karyotypes, and the use of VEN + HMA‐based regimens. This evidence concerns the gene TP53 and acute myeloid leukemia.